Avella Specialty Pharmacy joins limited distribution network for Imbruvica
PHOENIX — Drug makers Johnson & Johnson and Pharmacyclics have added Avella Specialty Pharmacy to their limited-distribution network for a newly approved blood cancer drug.
Avella said Thursday that it had joined the limited-distribution network for Imbruvica (ibrutinib), which the Food and Drug Administration approved this week for mantle cell lymphoma. Avella is one of five specialty pharmacies to join the network, the company said.
"We are proud to be a specialty pharmacy provider of Imbruvica capsules, now approved by the FDA for the treatment of patients with MCL," Avella VP business development Leslie Yendro said. "Avella has the ability to serve patients in all 50 states and to provide high-touch patient services and reliable product data to ensure maximum drug effectiveness."
New law encourages schools to stock epinephrine for allergic reactions
NEW YORK — New legislation signed into law Wednesday encourages states to adopt laws allowing schools to maintain a supply of emergency treatments for life-threatening allergy attacks.
Barack Obama signed the School Access to Emergency Epinephrine Act, under which schools could maintain a supply of epinephrine, which is the only first-line treatment for life-threatening allergic reactions, also known as anaphylaxis.
The legislation received praise from Mylan, a drug maker that produces EpiPen, a popular epinephrine injector pen.
"Recent tragedies have reinforced that when anaphylaxis occurs, every minute matters, and immediate access to epinephrine and emergency medical care is crucial," Mylan CEO Heather Bresch said. "The new federal law is a critical step for improving anaphylaxis preparedness in schools. We applaud those who worked tirelessly to make this bill a reality, from Congress, government officials and leading advocacy organizers to parents, caregivers, patients and healthcare professionals."
Onco360 added to limited-distribution network for J&J, Pharmacyclics blood cancer drug
NEW YORK — Johnson & Johnson and Pharmacyclics have added a New York-based specialty pharmacy company focused on cancer to their limited-distribution network for a drug recently approved for a rare form of blood cancer.
Onco360 said Wednesday that it had become part of the network for distributing Imbruvica (ibrutinib) capsules. The announcement came the same day that the Food and Drug Adminsitration announced the approval of Imbruvica (ibrutinib) for mantle cell lymphoma, or MCL.
"As one of the select few specialty pharmacies in the network, Onco360 is very proud to have been chosen by Pharmacyclics and Janssen Biotech," Onco360 CEO Burt Zweigenhaft said, referring to the J&J subsidiary that co-markets Imbruvica.
Limited-distribution networks are set up by drug companies in order to control the distribution of drugs, usually specialty drugs that are distributed only to a few select specialty pharmacies. While their purpose is to ensure more efficient production, distribution and use of the drugs, they also often exclude retail pharmacies.